Peptide Referee

ARA-290 (cibinetide): research, legal status and who sells it

This page is information, not medical advice. ARA-290 (cibinetide) is not approved as a medicine in the markets below unless stated. We don't publish dosing or usage instructions.

Also known as
Cibinetide, ARA290
Category
Erythropoietin-derived tissue-protective peptide
Evidence level
Early human trials
Price range
$1.75/mg to $15.04/mg, median $4.63/mg across 48 vendors (compare)
Our lab tests
None yet (how testing will work)
WhereStatus
United StatesNot FDA-approved; FDA lists cibinetide (ARA-290) in Category 3 (nominated without adequate support) for pharmacy compounding [1][2].
United KingdomNo UK-licensed medicine containing cibinetide (ARA-290) appears in the MHRA products database [3].
European UnionNo medicine containing cibinetide (ARA-290) is authorized in the EU, according to EMA's central and Article 57 product data [4][5].
CanadaNo product containing cibinetide (ARA-290) appears in Health Canada's Drug Product Database [6].
AustraliaCibinetide is not named in Australia's Poisons Standard (October 2026) [7].
Sport (WADA)Not named on the 2026 Prohibited List, but section S2 bans innate repair receptor agonists at all times [8], and research describes ARA-290 (cibinetide) as a selective agonist of that receptor [9].
 Summaries of official sources, checked —. Rules change; follow the source links. Not legal advice.

We haven't published a full overview of ARA-290 (cibinetide) yet. The legal status table and live prices on this page are current.

ARA-290 (cibinetide) prices: cheapest listings

The five lowest $/mg listings out of 66. See all ARA-290 (cibinetide) prices

Vendor Transparency Product Size Price $/mg vs median Stock Vendor's page
Bulk Peptide Wholesale 45/100* ARA-290 10 mg (10 vials) 10 mg × 10 $175 $1.75/mg −62% In stock View
Royal Peptides FDA warning letter, Aug 2026 52/100 ARA-290 30mgx10vials 30 mg × 10 $550 $1.83/mg −60% In stock View
Bulk Peptide Supply 57/100* ARA-290 10 mg 10 mg $20 $2.00/mg −57% In stock View
Bulk Peptide Supply 57/100* ARA-290 10 mg (10 vials) 10 mg × 10 $225 $2.25/mg −51% In stock View
NuLife Peptides 10/100* ARA-290 (20MG) 20 mg $45 $2.25/mg −51% In stock View

Prices come from each vendor's public product feed and were last fetched Oct 15, 2026. They exclude shipping and discounts. $/mg uses the labeled amount, not measured content. A transparency score marked * is based on fewer than six checks; checks we couldn't complete score 0. How we compare prices.

Sources

  1. Drugs@FDA: FDA-Approved Drugs (database searched by active ingredient). U.S. Food and Drug Administration. Accessed Oct 14, 2026
  2. 503A Categories Update for May 2026: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A. U.S. Food and Drug Administration. Accessed Oct 14, 2026
  3. MHRA Products: licensed-medicine search for "cibinetide". Medicines and Healthcare products Regulatory Agency (UK). Accessed Oct 14, 2026
  4. EMA medicines data: centrally authorised human medicines (export of 14 October 2026). European Medicines Agency. Accessed Oct 14, 2026
  5. EMA Article 57 product data: medicines authorised in the EU/EEA (data as of 9 October 2026). European Medicines Agency. Accessed Oct 14, 2026
  6. Drug Product Database online query (searched by active ingredient). Health Canada. Accessed Oct 14, 2026
  7. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327, registered 30 September 2026). Federal Register of Legislation, Australian Government. Accessed Oct 14, 2026
  8. World Anti-Doping Code International Standard: Prohibited List 2026 (in force 1 January 2026). World Anti-Doping Agency. Accessed Oct 14, 2026
  9. Targeting the innate repair receptor to treat neuropathy. Pain Reports (2016). Accessed Oct 15, 2026